

**UNITED STATES SECURITIES AND EXCHANGE
COMMISSION**

Washington, D.C. 20549

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF
SECURITIES**

OMB APPROVAL

OMB Number: 3235-0104

Estimated average burden

hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Di Salvo Giuseppe</u> (Last) (First) (Middle) <u>AVIENT CORPORATION</u> <u>33587 WALKER ROAD</u> (Street) <u>AVON LAKE OH 44012</u> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) <u>06/01/2026</u>	3. Issuer Name and Ticker or Trading Symbol <u>AVIENT CORP [AVNT]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> Officer (give title below) <u>SVP, Chief Financial Officer</u> 10% Owner Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
<u>Common Stock</u>	<u>18,300.401</u>	<u>I</u>	<u>Supplemental Plan⁽¹⁾</u>

**Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
<u>Restricted Stock Units</u>	<u>(2)</u>	<u>(2)</u>	<u>Common Stock</u>	<u>1,761</u>	<u>(3)</u>	<u>D</u>	
<u>Restricted Stock Units</u>	<u>(4)</u>	<u>(4)</u>	<u>Common Stock</u>	<u>1,179</u>	<u>(3)</u>	<u>D</u>	
<u>Restricted Stock Units</u>	<u>(5)</u>	<u>(5)</u>	<u>Common Stock</u>	<u>2,783</u>	<u>(3)</u>	<u>D</u>	
<u>Stock Appreciation Rights</u>	<u>(6)</u>	<u>02/11/2029</u>	<u>Common Stock</u>	<u>1,637</u>	<u>31.54</u>	<u>D</u>	
<u>Stock Appreciation Rights</u>	<u>(7)</u>	<u>02/10/2030</u>	<u>Common Stock</u>	<u>3,713</u>	<u>31.48</u>	<u>D</u>	
<u>Stock Appreciation Rights</u>	<u>(8)</u>	<u>02/08/2031</u>	<u>Common Stock</u>	<u>5,470</u>	<u>42.27</u>	<u>D</u>	
<u>Stock Appreciation Rights</u>	<u>(9)</u>	<u>02/14/2032</u>	<u>Common Stock</u>	<u>4,250</u>	<u>52.64</u>	<u>D</u>	
<u>Stock Appreciation Rights</u>	<u>(10)</u>	<u>02/17/2033</u>	<u>Common Stock</u>	<u>5,000</u>	<u>42.93</u>	<u>D</u>	
<u>Stock Appreciation Rights</u>	<u>(11)</u>	<u>02/22/2034</u>	<u>Common Stock</u>	<u>5,250</u>	<u>39.27</u>	<u>D</u>	

Explanation of Responses:

- The information in this report is based on a plan statement as of June 1, 2026.
- The restricted stock units vest 3 years from the date of grant on February 22, 2027.
- Each restricted stock unit represents a contingent right to receive one share of Avient common stock.
- The restricted stock units vest in substantially equal installments on each of February 19, 2027 and February 19, 2028, unless earlier vested or terminated pursuant to the terms of the grant agreement.
- The restricted stock units vest in substantially equal installments on each of February 20, 2027, February 20, 2028 and February 20, 2029, unless earlier vested or terminated pursuant to the terms of the grant agreement.
- Stock appreciation rights ("SARs") become exercisable and vest only upon the achievement of both price and time requirements. To vest, each one-third of the grant must attain 10%, 15% and 20% stock appreciation, respectively (which must be maintained for a minimum of thirty consecutive trading days) from the grant date closing price of \$31.54 per share and no more than one-third of the grant can vest per year during the first three years.
- SARs become exercisable and vest only upon the achievement of both price and time requirements. To vest, each one-third of the grant must attain 10%, 15% and 20% stock appreciation, respectively (which must be maintained for a minimum of thirty consecutive trading days) from the grant date closing price of \$31.48 per share and no more than one-third of the grant can vest per year during the first three years.
- SARs become exercisable and vest only upon the achievement of both price and time requirements. To vest, each one-third of the grant must attain 10%, 15% and 20% stock

appreciation, respectively (which must be maintained for a minimum of thirty consecutive trading days) from the grant date closing price of \$42.27 per share and no more than one-third of the grant can vest per year during the first three years

9. SARs become exercisable and vest only upon the achievement of both price and time requirements. To vest, each one-third of the grant must attain 10%, 15% and 20% stock appreciation, respectively (which must be maintained for a minimum of thirty consecutive trading days) from the grant date closing price of \$52.64 per share and no more than one-third of the grant can vest per year during the first three years.

10. SARs become exercisable and vest only upon the achievement of both price and time requirements. To vest, each one-third of the grant must attain 10%, 15% and 20% stock appreciation, respectively (which must be maintained for a minimum of twenty consecutive trading days) from the grant date closing price of \$42.93 per share and no more than one-third of the grant can vest per year during the first three years.

11. SARs become exercisable and vest only upon the achievement of both price and time requirements. To vest, each one-third of the grant must attain 10%, 15% and 20% stock appreciation, respectively (which must be maintained for a minimum of twenty consecutive trading days) from the grant date closing price of \$39.27 per share and no more than one-third of the grant can vest per year during the first three years.

Remarks:

Exhibit 24.1 - Power of Attorney

/s/ Robert K. James, Power
of Attorney for Giuseppe Di Salvo 06/01/2026

** Signature of Reporting Date
Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Know all by these presents that the undersigned hereby constitutes and appoints each of Amy M. Sanders, Kristen A. Gajewski, Robert K. James, Ari M. Friedman, Samuel V. Huryn, and Anne M. Stetz, signing singly, the undersigned's true and lawful attorney-in-fact to: 1. Prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the U.S. Securities and Exchange Commission (the "SEC") all forms and schedules, including Form ID, necessary to complete the timely enrollment of the undersigned in the SEC's Electronic Data Gathering, Analysis, and Retrieval ("EDGAR Next") system, and any and all amendments thereto; and 2. Do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete the execution of any such form or schedule and the timely filing of such form or schedule with the SEC; and 3. Do and perform any and all acts required as an account administrator of the undersigned's EDGAR Next account including, but not limited to, managing the undersigned's EDGAR Next account, as well as performing yearly acknowledgements and token management; and 4. Execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of Avient Corporation (the "Corporation"), Forms 3, 4, and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder; and 5. Do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, or 5 and timely file such form with the SEC and any stock exchange or similar authority; and 6. Take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion. The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Corporation assuming, any of the undersigned's responsibility to comply with Section 16 of the Securities Exchange Act of 1934. This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Corporation, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact. IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 29th day of April, 2026. /s/ Giuseppe Di Salvo